IP Library Granted Patent US 9,694,114
Granted Patent B2
US 9,694,114 · App. 14/910,473 · Granted Jul 4, 2017

Antimicrobial catheters with permeabilization agents

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,694,114
App. No.
14/910,473
Granted
Jul 4, 2017
Kind
B2
Abstract

Catheters and a method of preparation thereof comprising a catheter body and at least one connector. The catheter body has an exterior surface and at least one lumen having an aspect ratio of at least 3:1 and an intraluminal surface comprising a hydrophilic polymer layer thereon, the hydrophilic polymer layer has an average dry thickness of at least about 50 nanometers, wherein the catheter body comprises one or more permeabilization agents and one or more antimicrobial agents.

Claims (32)

1. A method of inhibiting microbial contamination in a catheter, the method comprising the step of:

infusing a lumen of the catheter with a hydrochloric acid solution having a concentration of 0.3 Molar to 1.0 Molar.

2. The method according to claim 1 , wherein the hydrochloric acid solution has a hydrochloric acid concentration of 0.3 Molar to 0.5 Molar.

3. The method according to claim 1 , further comprising the step of:

allowing the hydrochloric acid solution to dwell within the lumen for about an hour.

4. The method according to claim 3 , further comprising the step of:

drawing the hydrochloric acid solution from the lumen following the hour dwell time.

5. The method according to claim 4 , further comprising the step of:

flushing the catheter with a saline solution following the withdrawal of the hydrochloric acid solution.

6. The method according to claim 1 , wherein the hydrochloric acid solution further includes an antimicrobial agent.

7. The method according to claim 6 , wherein the antimicrobial agent includes silver sulfadiazine.

8. The method according to claim 7 , wherein the silver sulfadiazine is eluted from the catheter and configured to provide a concentration of at least 128 ppm of the silver sulfadiazine adjacent to a surface of the catheter.

9. The method according to claim 6 , wherein the antimicrobial agent includes Rifampin and Minocycline.

10. The method according to claim 1 , wherein the hydrochloric acid solution further includes an anti-coagulant.

11. The method according to claim 10 , wherein the anti-coagulant is heparin.

12. A method of treating a patient having a microbial contamination of an indwelling catheter, the method comprising the steps of:

infusing a lumen of the catheter with a hydrochloric acid solution having a concentration of 0.3 Molar to 1.0 Molar.

13. The method according to claim 12 , wherein the hydrochloric acid solution has a hydrochloric acid concentration of 0.3 Molar to 0.5 Molar.

14. The method according to claim 12 , further comprising the step of:

selecting a hydrochloric acid concentration of 0.4 Molar to 1.0 Molar in response to a biofilm of microbial contamination being present in the catheter.

15. The method according to claim 12 , further comprising the step of:

allowing the hydrochloric acid solution to dwell within the lumen for about 30 minutes.

16. The method according to claim 15 , further comprising the step of:

drawing the hydrochloric acid solution from the lumen following the hour dwell time.

17. The method according to claim 16 , further comprising the step of:

flushing the catheter with a saline solution following the withdrawal of the hydrochloric acid solution.

18. The method according to claim 12 , wherein the hydrochloric acid solution further includes an antimicrobial agent.

19. The method according to claim 18 , wherein the antimicrobial agent includes silver sulfadiazine.

20. The method according to claim 19 , wherein the silver sulfadiazine is eluted from the catheter and configured to provide a concentration of at least 128 ppm of the silver sulfadiazine adjacent to a surface of the catheter.

21. The method according to claim 18 , wherein the antimicrobial agent includes Rifampin and Minocycline.

22. The method according to claim 12 , wherein the hydrochloric acid solution further includes an anti-coagulant.

23. The method according to claim 22 , wherein the anti-coagulant is heparin.

Assignments (5)
SECURITY INTEREST Recorded Oct 3, 2019
From: ARROW INTERNATIONAL, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 050619/0681 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 038098 FRAME 0482. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 22, 2018
From: LUCCHINO, DAVID; LOOSE, CHRISTOPHER R.
To: SEMPRUS BIOSCIENCES CORP.
Reel/Frame 045417/0540 →
SECURITY INTEREST Recorded Feb 21, 2017
From: ARROW INTERNATIONAL, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 041759/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2017
From: SEMPRUS BIOSCIENCES CORP.
To: ARROW INTERNATIONAL, INC.
Reel/Frame 041192/0579 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2016
From: LUCCHINO, DAVID; LOOSE, CHRISTOPHER R.
To: SEMPRUS BIOSCHIENCES CORP.
Reel/Frame 038098/0482 →